787
Participants
Start Date
October 27, 2014
Primary Completion Date
June 3, 2015
Study Completion Date
April 20, 2016
OnabotulinumtoxinA
OnabotulinumtoxinA injected into the protocol-specified areas. Subjects will receive at least 1 and up to 3 treatments.
Normal Saline
Placebo (normal saline) injected into the protocol-specified areas on Day 1.
The Center For Dermatology Cosmetic and Laser Surgery, Mount Kisco
Baumann Cosmetic & Research Institute, Miami
Tennessee Clinical Research Center, Nashville
Saint Louis University, St Louis
The Petrus Center for Aesthetic, Little Rock
The Center for Skin Research, Houston
Westside Aesthetics, Los Angeles
Eye Research Foundation, Newport Beach
Steve Yoelin, MD Medical Associates, Inc., Newport Beach
Premier Clinical Research, Spokane
Aalst Dermatology Clinic, Aalst
UZ Brussel, Jette
Medical Skin Care - Sint-Truiden, Limbourg
Rosenpark Research, Darmstadt
Hautzentrum Koeln (Cologne Dermatology), Köln Nordrhein-Westfalen
Hautok und hautok-cosmetics, München
Praxisgemeinschaft Theatiner46, München
Hautzentrum am Starnberger See GmbH, Starnberg
CentroDerm Study Center, Wuppertal
Shakespeare House Health Centre, General Practice, Basingstoke
Medizen Clinic, Birmingham
The Bosham Clinic, Chichester
Waverlery Medical Practice, Coatbridge
The Gatehouse, Whitegate
Lead Sponsor
Allergan
INDUSTRY